In Brief: Diagnostic Products Corp.
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp.: Receives FDA clearance to market its radioimmunoassay kit for prostate specific antigen (PSA). DPC says that clinical trials have begun for two additional prostate cancer markers, designed for use on the firm's "automated random-access" Immulite system. The assays include a third-generation PSA kit with "exquisite sensitivity"